Summary:
This study investigates the efficacy and safety of rimegepant, a CGRP receptor antagonist, in treating acute migraines in children and adolescents aged 6 to 17. It aims to provide a new therapeutic option for this demographic, which currently has limited treatment choices. The study is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Participants are assessed for pain freedom, symptom relief, and the need for rescue medication post-dose. Outcomes focus on pain relief, symptom management, and functional ability.
Qualified Participants Must:
• Age ≥6 to <18 years.
•
History of migraine for >6 months.
•
1-8 moderate/severe migraine attacks per month in last 2 months.
•
Stable prophylactic migraine medication dose for 12 weeks prior.
•
Ability to distinguish between migraine and other headaches.
•
Weight >40 kg.
Qualified Participants May Receive:
Compensation for time and travel